A handheld device for diagnosing the early signs of osteoporosis could be available for clinical use within five years.
The technology is currently being refined and tested at the University of Southampton with support from the Engineering and Physical Sciences Research Council (EPSRC). The original concept was invented at the University of California, Santa Barbara.
Unlike existing methods of assessing bone fragility, which measure bone density using X-rays, the device is designed to measure the ability of bone tissue to prevent small cracks growing into full-blown fractures.
It does this by pressing a microscopic needle a tiny distance into the top layer of bone. Measured electronically, the amount of penetration indicates how fragile the bone tissue is and therefore the risk of experiencing an osteoporotic fracture later in life.
Osteoporosis is often referred to as fragile bone disease. However, for many sufferers, the first indication that they have the condition is when they actually sustain a fracture.
Drugs can slow or arrest the development of the disease, but the condition may already be quite advanced by the time the first break has happened. Doctors can estimate an individual’s risk of fracturing by using bone-density measurements and other factors such as age, gender, smoking and any history of fracturing. But the new microindentation technology affordably delivers a fundamentally different measurement that has huge potential to refine such an evaluation.
A normal reading might see the needle sink into the bone by around 20 micrometres (0.02 mm); a reading of 40 micrometres might indicate a significant risk of fracture.
“As the population ages and life expectancy rises in the decades ahead, the cost of treating osteoporotic fractures will increase,” says Professor Philipp Thurner of the University of Southampton, who is leading the project. “One in three women aged over 50 is forecast to experience an osteoporotic fracture in her lifetime and, globally, treatment costs are forecast to reach over US$130 billion by 2050. The potential improvement in assessing osteoporosis and future fracture risk offered by this new technology could reduce the burden of broken bones for individuals, healthcare systems and the economy.
The Latest on: Osteoporosis
- Top stories in endocrinology: FDA approves romosozumab for osteoporosis; Congressional hearing into 'broken system' behind insulin prices on April 17, 2019 at 2:15 pm
Among the top stories in endocrinology last week were the FDA approving romosozumab to treat osteoporosis in postmenopausal women at high risk for fracture and the three manufacturers of insulin and ... […]
- New Osteoporosis Drug Evenity Approved by the FDA on April 17, 2019 at 11:45 am
Deciding on a drug therapy to prevent fracture in osteoporosis has been an either/or proposition for doctors. People with osteoporosis could either take a medication to slow down bone loss or take one ... […]
- Pharmalittle: Stronger warnings urged for Amgen’s osteoporosis drug; prices in drug ads can be jarring on April 17, 2019 at 5:47 am
Good morning. Elizabeth Cooney reporting from STAT’s worldwide headquarters in Boston today, with contributions from Ed Silverman before he takes a break from the news in favor of a cultural excursion ... […]
- New Treatment for Osteoporosis In Postmenopausal Women is Available on April 16, 2019 at 7:38 am
Amgen’s romosozumab-aqqg therapy (Evenity) for osteoporosis in postmenopausal women is now available for shipment to wholesalers in the United States. Approved by the FDA on April 9, 2019, the ... […]
- EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture on April 15, 2019 at 10:30 pm
New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that EVENITY ... […]
- The facts about osteoporosis on April 15, 2019 at 3:20 pm
Osteoporosis is often seen as a problem for the elderly, and the National Osteoporosis Foundation notes that being over 50 is a major risk factor for osteoporosis. But that doesnÕt mean people ... […]
- How Lifestyle Choices Might be Putting You at Risk for Osteoporosis on April 15, 2019 at 3:02 pm
Many people are only vaguely familiar with osteoporosis, a disease which results in reduced bone density and quality. It’s often viewed as a normal part of the aging process. While age is a risk ... […]
- FDA Approves New Osteoporosis Treatment on April 11, 2019 at 5:31 am
TUESDAY, April 9, 2019 (HealthDay News) -- Many aging Americans face the risk of fractures due to osteoporosis. Now, they have a new means of fighting back, thanks to the U.S. Food and Drug ... […]
- New research could prevent jaw damage in patients being treated for cancer or osteoporosis on April 11, 2019 at 5:16 am
USC researchers and collaborators report a breakthrough to prevent damage to the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis. The newly published ... […]
- Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug on April 10, 2019 at 7:56 pm
Amgen, Inc. (NASDAQ: AMGN) — which was in the news late last week over a legal battle with Novartis AG (NYSE: NVS) over their migraine drug collaboration — now has a positive FDA decision to ... […]
via Google News and Bing News